NCT04085029 Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
| NCT ID | NCT04085029 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Duke University |
| Condition | Oligometastasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2019-09-26 |
| Primary Completion | 2029-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2019-09-26 with a primary completion date of 2029-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years of age * Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment * Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s) * Patient must sign study-specific informed consent Exclusion Criteria: • None
Contact & Investigator
Joseph Salama, MD
PRINCIPAL INVESTIGATOR
Duke University
Frequently Asked Questions
Who can join the NCT04085029 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Oligometastasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04085029 currently recruiting?
Yes, NCT04085029 is actively recruiting participants. Contact the research team at RadOnc-Clinical_Trials@dm.duke.edu for enrollment information.
Where is the NCT04085029 trial being conducted?
This trial is being conducted at Cary, United States, Durham, United States, Durham, United States, Raleigh, United States and 1 additional location.
Who is sponsoring the NCT04085029 clinical trial?
NCT04085029 is sponsored by Duke University. The principal investigator is Joseph Salama, MD at Duke University. The trial plans to enroll 300 participants.